Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Eur J Gastroenterol Hepatol
    October 2026
  1. KARIM A, Alam T, Masood M, Kumari K, et al
    Beyond tissue drug concentrations: additional considerations in anti-tumor necrosis factor penetration among patients with perianal fistulizing Crohn's disease.
    Eur J Gastroenterol Hepatol. 2026;38:1239.
    >> Share

    September 2026
  2. SABHAN H, Bello F, Muhsen S, Johansson F, et al
    Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2026 Sep 1. doi: 10.1097/MEG.0000000000003274.
    >> Share

    August 2026
  3. NAPOLITANO D, Bozzetti M, Scaldaferri F, Gasbarrini A, et al
    Generational differences in illness perception among adults with inflammatory bowel disease: a multicenter cross-sectional study.
    Eur J Gastroenterol Hepatol. 2026 Aug 27. doi: 10.1097/MEG.0000000000003266.
    >> Share

  4. DIVAKARLA S, Hinckfuss C, Cruz C, Luo H, et al
    The role of bioelectrical impedance analysis in assessing sarcopenia in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Aug 12. doi: 10.1097/MEG.0000000000003265.
    >> Share

  5. SUBEDI A, Chaar A, Suhail FK, Hussain A, et al
    Indirect comparison of endoscopic balloon dilatation, stent placement, and stricturotomy for lower gastrointestinal strictures in Crohn's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2026;38:933-940.
    >> Share

  6. TURSI A, Elisei W, Terlizzi AP, Antonino N, et al
    Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy.
    Eur J Gastroenterol Hepatol. 2026;38:902-908.
    >> Share

    July 2026
  7. HABIBOVIC A, Dizdarevic N, Tulumovic E, Selimovic N, et al
    Evolution of surgical risk in Crohn's disease: impact of the biologic therapy era on time to first surgery in a Bosnian tertiary referral center.
    Eur J Gastroenterol Hepatol. 2026 Jul 24. doi: 10.1097/MEG.0000000000003257.
    >> Share

  8. PSARAKIS G, Drygiannakis I, Foteinogiannopoulou K, Orfanoudaki E, et al
    Renal and urological complications in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Jul 22. doi: 10.1097/MEG.0000000000003249.
    >> Share

  9. COUTO SOUSA D, Fernandes SR, Da Silva Neves A, Pereira F, et al
    External validation of a prediction score for identifying a mild course of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2026 Jul 20. doi: 10.1097/MEG.0000000000003242.
    >> Share

  10. GIRI S, Vizhi K, Angadi S, Afzalpurkar S, et al
    Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
    Eur J Gastroenterol Hepatol. 2026 Jul 20. doi: 10.1097/MEG.0000000000003254.
    >> Share

  11. FARAH A, Mari A
    Interpretation of surgical recurrence in the dynamic phenotype of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2026;38:884.
    >> Share

  12. BINDER IMH, Brynskov J, Attauabi M
    Chest X-ray prior to biological treatment in inflammatory bowel diseases: it is not only about tuberculosis - a case report and literature review.
    Eur J Gastroenterol Hepatol. 2026;38:836-839.
    >> Share

    June 2026
  13. INCE OZGENEL F, Tulek Z, Temel T
    Effect of a nurse-led individualized patient education program on fatigue and quality of life in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Jun 29. doi: 10.1097/MEG.0000000000003241.
    >> Share

  14. GIRI S, Kulkarni A, Harindranath S, Malakar S, et al
    Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis - a network meta-analysis of randomized trials.
    Eur J Gastroenterol Hepatol. 2026 Jun 29. doi: 10.1097/MEG.0000000000003240.
    >> Share

  15. MIYAKE Y, Tanaka K, Nagata C, Furukawa S, et al
    Dietary B vitamin intake and risk of ulcerative colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2026 Jun 23. doi: 10.1097/MEG.0000000000003217.
    >> Share

  16. BODGER K, Taylor F, Rai P, Dobson L, et al
    Factors associated with preference for in-person versus remote consultations in inflammatory bowel disease in the United Kingdom: secondary analysis of an online survey.
    Eur J Gastroenterol Hepatol. 2026 Jun 4. doi: 10.1097/MEG.0000000000003220.
    >> Share

  17. MALKOPOULOS A, Subhaharan D, James R, Jones M, et al
    Management of endoscopic rectal activity in ulcerative colitis: real-world adherence to guidelines and clinical outcomes.
    Eur J Gastroenterol Hepatol. 2026 Jun 2. doi: 10.1097/MEG.0000000000003228.
    >> Share

  18. GUVEN IE
    Letter to the editor regarding 'Correlation between infliximab trough levels and postoperative endoscopic recurrence in patients with Crohn's disease'.
    Eur J Gastroenterol Hepatol. 2026;38:779.
    >> Share

  19. MORAES BF, Suffert LC, Cancado GGL
    Appendicectomy in active ulcerative colitis: is the evidence strong enough to support clinical recommendation? A critical appraisal.
    Eur J Gastroenterol Hepatol. 2026;38:777-778.
    >> Share

  20. CHEN Z, Lin X, Chen M
    Comment on 'Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study'.
    Eur J Gastroenterol Hepatol. 2026;38:774-775.
    >> Share

    April 2026
  21. XU Y, Wu K, Liu P, Ni C, et al
    Prevalence, risk factors, and clinical outcomes of extraintestinal manifestations in inflammatory bowel disease: a population-based study in china.
    Eur J Gastroenterol Hepatol. 2026 Apr 6. doi: 10.1097/MEG.0000000000003197.
    >> Share

  22. FERRANTE M, Christensen B, Bressler B, Bassel M, et al
    Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion study.
    Eur J Gastroenterol Hepatol. 2026 Apr 6. doi: 10.1097/MEG.0000000000003193.
    >> Share

  23. PRODANOVA D, Janeva A, Drobne D, Novak G, et al
    Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatment.
    Eur J Gastroenterol Hepatol. 2026;38:455-460.
    >> Share

  24. SONG T, Chen Y, Zhang C, Sun Z, et al
    Stricturing phenotype is associated with an increased risk of postoperative surgical recurrence in isolated small bowel Crohn's disease.
    Eur J Gastroenterol Hepatol. 2026;38:442-449.
    >> Share

  25. COELHO RODRIGUES I, Fernandes SR, Saraiva S, Goncalves AR, et al
    Fecal calprotectin-guided treatment escalation strategy enhances disease clearance in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026;38:431-436.
    >> Share

    March 2026
  26. RZETELNA H, Santo P, de Souza HSP, Nichols J, et al
    Positive conversion of latent tuberculosis screening in patients with inflammatory bowel disease on antitumor necrosis factor alpha drugs: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003180.
    >> Share

  27. DEYHIM T, Saraga A, Gade A, Geeganage G, et al
    Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003183.
    >> Share

  28. ZEWDU WS, Zerihun TE, Emiru ZA, Dagnew SB, et al
    Medication adherence level and its predictors among inflammatory bowel disease sufferers in a resource-strained healthcare setting.
    Eur J Gastroenterol Hepatol. 2026 Mar 6. doi: 10.1097/MEG.0000000000003166.
    >> Share

  29. FOTEINOGIANNOPOULOU K, Nikolaou P, Orfanoudaki E, Theodoraki E, et al
    The rate and risk factors for malignancy in patients with inflammatory bowel disease in Crete: a case control study.
    Eur J Gastroenterol Hepatol. 2026;38:327-332.
    >> Share

    February 2026
  30. OIWA K, Yamamura T, Nakamura M, Maeda K, et al
    Total biopsy via endoscopic submucosal dissection is useful for the diagnosis of neoplastic lesions in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1097/MEG.0000000000003165.
    >> Share

  31. ANANDABASKARAN S, Liu Z, Hanna L, Lung P, et al
    Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.
    Eur J Gastroenterol Hepatol. 2026 Feb 24. doi: 10.1097/MEG.0000000000003169.
    >> Share

  32. SLEUTJES JAM, van de Pol N, van der Meer AJ, de Man RA, et al
    Cardiovascular risk profiles in patients with primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 23. doi: 10.1097/MEG.0000000000003146.
    >> Share

  33. GUIMARAES A, Caetano AC, Barbosa I, Costa D, et al
    Validation of the Urgency Numeric Rating Scale and correlation with endoscopic, histological, and manometric activity in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 10. doi: 10.1097/MEG.0000000000003155.
    >> Share

    January 2026
  34. GALTS CPC, Anvari S, Haq M, Grossman K, et al
    Second-line infliximab therapy for ulcerative colitis (SLIT-UC): a retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2026 Jan 13. doi: 10.1097/MEG.0000000000003132.
    >> Share

  35. NATHA C, Colli Cruz C, Vemulapalli V, Sullivan A, et al
    Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapy.
    Eur J Gastroenterol Hepatol. 2026 Jan 6. doi: 10.1097/MEG.0000000000003124.
    >> Share

    December 2025
  36. TANG L, Mo J, Ouyang J, Li W, et al
    A multilevel analysis of the genetic association between inflammatory bowel disease and primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2025 Dec 9. doi: 10.1097/MEG.0000000000003116.
    >> Share

  37. BEVIVINO G, Scarozza P, Zerboni G, Iacopini F, et al
    Infliximab-induced pulmonary interstitial disease in a male patient with ulcerative colitis: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2025;37:1402-1405.
    >> Share

    November 2025
  38. BUCHNER AM, Kohen R, Sonnenberg A
    Epstein-Barr virus infection increases the risk for inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Nov 26. doi: 10.1097/MEG.0000000000003109.
    >> Share

  39. SUN Z, Zhu Z, Yang R, Cao L, et al
    Correlation between infliximab trough levels and postoperative endoscopic recurrence in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2025 Nov 5. doi: 10.1097/MEG.0000000000003088.
    >> Share

    October 2025
  40. SILBER JL, Norman JM, Kanno T, Crossette EM, et al
    A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in he
    Eur J Gastroenterol Hepatol. 2025 Oct 23. doi: 10.1097/MEG.0000000000003098.
    >> Share

  41. WONG ECL, Khan N, Dulai PS, Marshall JK, et al
    Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trial.
    Eur J Gastroenterol Hepatol. 2025 Oct 20. doi: 10.1097/MEG.0000000000003092.
    >> Share

  42. VIAZIS N, Toruner M, Papastergiou V, Mousourakis K, et al
    Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study.
    Eur J Gastroenterol Hepatol. 2025 Oct 7. doi: 10.1097/MEG.0000000000003083.
    >> Share

  43. BRAASCH T, Siegmund B
    The role of chest X-ray in latent tuberculosis infection screening for inflammatory bowel disease patients in low-incidence countries: in response to Gatt et al. (Eur J Gastroenterol Hepatol 2025;37:728-732).
    Eur J Gastroenterol Hepatol. 2025;37:1186.
    >> Share

    September 2025
  44. QIN Y, He C, Zhong N, Guo L, et al
    Exploring the molecular mechanism of Crohn's disease and rheumatoid arthritis: a bioinformatics and functional analysis approach.
    Eur J Gastroenterol Hepatol. 2025 Sep 8. doi: 10.1097/MEG.0000000000003068.
    >> Share

  45. TAMIMI TA, Abu-Farsakh N, AlRyalat SA, Obeidat K, et al
    Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Sep 5. doi: 10.1097/MEG.0000000000003067.
    >> Share

    August 2025
  46. PARKASH N, Keung C, Bell SJ, Moore GT, et al
    Evaluating the completeness of postoperative endoscopic recurrence assessment in Crohn's disease patients with Kono-S anastomoses.
    Eur J Gastroenterol Hepatol. 2025 Aug 25. doi: 10.1097/MEG.0000000000003063.
    >> Share

  47. LU G, Sun J, Du H
    Feasibility and Preliminary Efficacy of combined home-based fecal calprotectin self-testing and therapeutic drug monitoring-guided intervention in Patients with moderate-to-severe inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Aug 15. doi: 10.1097/MEG.0000000000003061.
    >> Share

  48. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.
    Eur J Gastroenterol Hepatol. 2025;37:985-986.
    >> Share

  49. RIVA A, Arienti G, Zuin G, Spini L, et al
    Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.
    Eur J Gastroenterol Hepatol. 2025;37:917-921.
    >> Share

    July 2025
  50. MICALLEF S, Mintoff F, Ellul P, Sciberras M, et al
    Nourishing remission: the role of Crohn's disease exclusion diet and partial enteral nutrition in pregnancy: a comprehensive review.
    Eur J Gastroenterol Hepatol. 2025 Jul 22. doi: 10.1097/MEG.0000000000003050.
    >> Share

  51. EALIWA N, Alamour W, Abu-Tailakh M, Eraki L, et al
    Clinical characteristics and long-term outcomes among inflammatory bowel disease patients of different ethnic groups: a case-control study.
    Eur J Gastroenterol Hepatol. 2025 Jul 18. doi: 10.1097/MEG.0000000000003047.
    >> Share

  52. MANTAKA A, Apostolakis I, Domeyer PR, Sarafis P, et al
    Quality of care in inflammatory bowel disease from patient's perspective using QUOTE-IBD: a Greek multicenter prospective study.
    Eur J Gastroenterol Hepatol. 2025 Jul 14. doi: 10.1097/MEG.0000000000003031.
    >> Share

  53. HUANG C, Czuber-Dochan W, Norton C
    Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study.
    Eur J Gastroenterol Hepatol. 2025 Jul 14. doi: 10.1097/MEG.0000000000003034.
    >> Share

    June 2025
  54. DI PAOLO MC, Cassinotti A, Pagnini C, Ceccarelli L, et al
    Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists.
    Eur J Gastroenterol Hepatol. 2025 Jun 26. doi: 10.1097/MEG.0000000000003025.
    >> Share

  55. PUGLIESE N, Bezzio C, Festa S, Caprioli FA, et al
    Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003016.
    >> Share

  56. COUTO SOUSA D, Fernandes SR, Saraiva S, Goncalves AR, et al
    Outcomes of acute severe ulcerative colitis at initial presentation.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003015.
    >> Share

  57. CROSEWSKI NI, Pereira AHM, Kotze LR, Pedroso MLA, et al
    Hepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003022.
    >> Share

    May 2025
  58. SCALVINI D, Bezzio C, Maimaris S, Lenti MV, et al
    A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.
    Eur J Gastroenterol Hepatol. 2025 May 19. doi: 10.1097/MEG.0000000000003005.
    >> Share

  59. SZLAK J, Magdziak A, Mroz A, Wieszczy-Szczepanik P, et al
    Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.
    Eur J Gastroenterol Hepatol. 2025 May 12. doi: 10.1097/MEG.0000000000003001.
    >> Share

  60. MORGAN M, Loel B, Lang R, Reilly C, et al
    The use of oral antibiotic cocktail in medically refractory paediatric acute severe colitis: a case series.
    Eur J Gastroenterol Hepatol. 2025;37:594-599.
    >> Share

    April 2025
  61. COLWILL M, Baillie S, Radia C, White S, et al
    The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Apr 30. doi: 10.1097/MEG.0000000000002995.
    >> Share

    March 2025
  62. GATT Y, Chatlani D, Camilleri C, Sciberras M, et al
    The role of chest X-ray in detecting latent tuberculosis among patients with low-risk inflammatory bowel disease before advanced therapy.
    Eur J Gastroenterol Hepatol. 2025 Mar 26. doi: 10.1097/MEG.0000000000002975.
    >> Share

  63. PATRA S, Chaudhary S, Samal SC, Ayyanar P, et al
    FoxP3-positive T regulatory cells and its effector mechanisms in Crohn's disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies.
    Eur J Gastroenterol Hepatol. 2025 Mar 24. doi: 10.1097/MEG.0000000000002971.
    >> Share

  64. YUKSEL I, Cagir Y, Durak MB, Atay A, et al
    A comparison between the Bowel Ultrasound Score and International Bowel Ultrasound Segmental Activity Score based on ileocolonoscopy in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2025 Mar 18. doi: 10.1097/MEG.0000000000002969.
    >> Share

  65. GODOY FINGER AP, Tavares Ferreira de Oliveira Cruz L, Rosevics L, de Queiroz-Telles F, et al
    Management of sporotrichosis in patients with inflammatory bowel disease using biological therapy (antitumor necrosis factor).
    Eur J Gastroenterol Hepatol. 2025;37:370-375.
    >> Share

  66. HANZEL J, Novak G, Jairath V, Zou G, et al
    Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot study.
    Eur J Gastroenterol Hepatol. 2025;37:304-307.
    >> Share

  67. TE GROEN M, Derks MEW, Nagtegaal ID, Peters CP, et al
    Gastrointestinal pathologist consensus of revised high-grade dysplasia in inflammatory bowel disease impacts the advanced neoplasia rate: a multicenter study.
    Eur J Gastroenterol Hepatol. 2025;37:287-294.
    >> Share

    February 2025
  68. JANSEN FM, den Broeder N, van Hal TW, Mahler EAM, et al
    Characteristics, risk factors, and disease course of musculoskeletal manifestations in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 21. doi: 10.1097/MEG.0000000000002921.
    >> Share

  69. OJAGHI SHIRMARD F, Pourfaraji SM, Saeedian B, Bagheri T, et al
    The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2025 Feb 18. doi: 10.1097/MEG.0000000000002952.
    >> Share

  70. SUPOVEC E, Hanzel J, Novak G, Manevski D, et al
    First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2025 Feb 6. doi: 10.1097/MEG.0000000000002940.
    >> Share

  71. MOLANDER P, Af Bjorkesten CG, Henricson H, Koskela R, et al
    Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 5. doi: 10.1097/MEG.0000000000002939.
    >> Share

  72. BASSOTTI G, Del Sordo R, Lanzarotto F, Mino S, et al
    Claudin-2 simplifies histological assessment of activity/remission of ulcerative colitis in real-life daily practice.
    Eur J Gastroenterol Hepatol. 2025 Feb 4. doi: 10.1097/MEG.0000000000002938.
    >> Share

  73. ZARKER AW, Wang Y
    Combination vedolizumab and ustekinumab for refractory Crohn's disease after immune checkpoint inhibitors.
    Eur J Gastroenterol Hepatol. 2025;37:240-241.
    >> Share

    January 2025
  74. LIATSOS C, Tzouvala M, Michalopoulos G, Giouleme O, et al
    Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.
    Eur J Gastroenterol Hepatol. 2025 Jan 23. doi: 10.1097/MEG.0000000000002926.
    >> Share

  75. KOHLI I, Thind N, Bhalla A, Attri A, et al
    Sarcopenia is associated with worse outcomes in patients with inflammatory bowel disease: insights from US national hospitalization data.
    Eur J Gastroenterol Hepatol. 2025;37:55-61.
    >> Share

  76. ALHALABI MM, Almokdad R
    The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis.
    Eur J Gastroenterol Hepatol. 2025;37:1-9.
    >> Share

  77. ELFORD AT, Heldt R, Kamal S, Christensen B, et al
    Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2025;37:47-54.
    >> Share

    November 2024
  78. ALBSHESH A, Abend A, Yehuda RM, Mahajna H, et al
    Intestinal ultrasound accurately predicts future therapy failure in Crohn's disease patients in a biologics-induced remission.
    Eur J Gastroenterol Hepatol. 2024 Nov 8. doi: 10.1097/MEG.0000000000002883.
    >> Share

  79. KOPPELMAN LJM, Maljaars PWJ, Voorneveld PW, van der Meulen-de Jong AE, et al
    Healthcare utilisation patterns and drivers amongst inflammatory bowel disease patients in the outpatient clinic.
    Eur J Gastroenterol Hepatol. 2024 Nov 5. doi: 10.1097/MEG.0000000000002880.
    >> Share

  80. SUN Z, Li Y
    After nonsurgical treatment of penetrating Crohn's disease: indications for subsequent surgical intervention.
    Eur J Gastroenterol Hepatol. 2024;36:1353-1354.
    >> Share

  81. DURAK MB
    Nonsurgical approach in penetrating Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024;36:1352.
    >> Share

  82. FERREIRA AI, Lima Capela T, Arieira C, Xavier S, et al
    Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Eur J Gastroenterol Hepatol. 2024;36:1314-1318.
    >> Share

    October 2024
  83. SELIN KA, Andersson S, Bilen K, Strid H, et al
    Variation in nutritional therapy practices: results of a survey on nutritional management of severe inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1097/MEG.0000000000002872.
    >> Share

  84. DAUNGSUPAWONG H, Wiwanitkit V
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet: correspondence.
    Eur J Gastroenterol Hepatol. 2024;36:1243.
    >> Share

    September 2024
  85. PAPATHANASIOU E, Kokkotis G, Axiaris G, Bellou G, et al
    Pregnancy outcomes in Greek women with inflammatory bowel disease: a longitudinal national retrospective study.
    Eur J Gastroenterol Hepatol. 2024 Sep 23. doi: 10.1097/MEG.0000000000002844.
    >> Share

  86. SABHAN H, Bello F, Muhsen S, Borin A, et al
    Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2024 Sep 20. doi: 10.1097/MEG.0000000000002854.
    >> Share

  87. CESARO N, Valvano M, Monaco S, Stefanelli G, et al
    The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002842.
    >> Share

  88. ALDIABAT M, Alhuneafat L, Al Ta'ani O, Altarawneh S, et al
    Inflammatory bowel disease and pulmonary embolism: a nationwide perspective.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002851.
    >> Share

  89. LOW ES, Greeve T, Boyapati RK, Moore GT, et al
    Characteristics of the Kono-S anastomosis in Crohn's disease patients using intestinal ultrasound.
    Eur J Gastroenterol Hepatol. 2024;36:1150-1152.
    >> Share

  90. COELHO R, Goncalves R, Mendes F, Macedo G, et al
    Gastroenterology healthcare in LGBTQ+ individuals.
    Eur J Gastroenterol Hepatol. 2024;36:1059-1067.
    >> Share

    August 2024
  91. DU J, Xu F, Qiu X, Hu X, et al
    A novel computed tomography enterography radiomics combining intestinal and creeping fat features could predict surgery risk in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Aug 23. doi: 10.1097/MEG.0000000000002839.
    >> Share

  92. NEAMTI L, Drugan TC, Drugan C, Silaghi C, et al
    Assessing seasonal variations of biomarkers in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:993-999.
    >> Share

    July 2024
  93. KAMEL AY, Johnson ZD, Hernandez I, Nguyen C, et al
    Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 16. doi: 10.1097/MEG.0000000000002821.
    >> Share

  94. KHALAF R, Sciberras M, Ellul P
    The role of the fecal microbiota in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002818.
    >> Share

  95. NAQVI HA, Delungahawatta T, Atarere JO, Bandaru SK, et al
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002815.
    >> Share

  96. KOLEHMAINEN S, Rautakorpi J, Loyttyniemi E, Af Bjorkesten CG, et al
    Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002816.
    >> Share

  97. MILIOLI NJ, Fernandes MV, Correa TL, Antunes V, et al
    Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 2. doi: 10.1097/MEG.0000000000002817.
    >> Share

  98. OZTURK O, Celebi G, Duman UG, Kupcuk E, et al
    Short-chain fatty acid levels in stools of patients with inflammatory bowel disease are lower than those in healthy subjects.
    Eur J Gastroenterol Hepatol. 2024;36:890-896.
    >> Share

    June 2024
  99. TORIS LD, Minsart CF, Husson CP, Franchimont DP, et al
    Lipopolysaccharide-binding protein in Crohn's disease patients: a promising noninvasive biomarker monitoring disease activity.
    Eur J Gastroenterol Hepatol. 2024 Jun 26. doi: 10.1097/MEG.0000000000002811.
    >> Share

  100. FIERENS L, Bossuyt P, Baert F, Baert D, et al
    Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jun 19. doi: 10.1097/MEG.0000000000002804.
    >> Share

  101. CHHIBBA T, Wong ECL, Reinisch W, Targownik L, et al
    Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
    Eur J Gastroenterol Hepatol. 2024;36:704-711.
    >> Share

    May 2024
  102. FREEMAN HJ
    Osteonecrosis (avascular necrosis) in inflammatory bowel disease: an extraintestinal clinical feature, not caused by corticosteroids.
    Eur J Gastroenterol Hepatol. 2024;36:503-504.
    >> Share

    April 2024
  103. YUAN B, Huang P, Yang M, Tang G, et al
    Intestinal ultrasound scan predicts corticosteroid failure and colectomy risk in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2024 Apr 17. doi: 10.1097/MEG.0000000000002780.
    >> Share

  104. WESTON F, Carter B, Powell N, Young AH, et al
    Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002768.
    >> Share

  105. SUN Z, Cao L, Chen Y, Zhu W, et al
    Long-term outcomes of intestinal penetrating Crohn's disease following successful nonoperative management.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002775.
    >> Share

  106. TEPES K, Hanzel J, Stubljar D, Strmsek K, et al
    Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Eur J Gastroenterol Hepatol. 2024 Apr 2. doi: 10.1097/MEG.0000000000002771.
    >> Share

  107. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    >> Share

  108. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    >> Share

  109. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    >> Share

    March 2024
  110. ZAGOROWICZ E, Binowski G, Strzadala D, Pruszko C, et al
    Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland.
    Eur J Gastroenterol Hepatol. 2024 Mar 19. doi: 10.1097/MEG.0000000000002764.
    >> Share

  111. ROKKAS T, Gisbert JP, Ekmektzoglou K, Dassopoulos T, et al
    Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Mar 12. doi: 10.1097/MEG.0000000000002751.
    >> Share

  112. STEPHENS IJB, Murphy B, Burns L, McCawley N, et al
    Contemporary perioperative outcomes after total abdominal colectomy for ulcerative colitis in a tertiary referral centre.
    Eur J Gastroenterol Hepatol. 2024 Mar 11. doi: 10.1097/MEG.0000000000002755.
    >> Share

  113. MOGILEVSKI T, Nguyen AL, Ajamian M, Smith R, et al
    Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:271-280.
    >> Share

  114. FIORINO G, Colombel JF, Katsanos K, Mearin F, et al
    Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy.
    Eur J Gastroenterol Hepatol. 2024 Mar 1. doi: 10.1097/MEG.0000000000002740.
    >> Share

    February 2024
  115. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
    Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
    >> Share

    January 2024
  116. KIRKIK D, Kalkanli Tas S, Tanoglu A
    Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1097/MEG.0000000000002695.
    >> Share

    December 2023
  117. MANTZARIS GJ, Bressler B, Adsul S, Luo M, et al
    Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002690.
    >> Share

  118. VIAZIS N, Manolakis A, Vraka M, Mylonas I, et al
    Anal defecatory function in ulcerative colitis patients after total proctocolectomy and ileal pouch-anal anastomosis: a prospective cohort study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002706.
    >> Share

  119. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
    Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
    >> Share

  120. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
    Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
    Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
    >> Share

    November 2023
  121. NGUYEN AL, Herath M, Burns M, Holt D, et al
    The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
    >> Share

    October 2023
  122. LIU C, Liu X, Shi H, Chen F, et al
    The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Oct 18. doi: 10.1097/MEG.0000000000002670.
    >> Share

  123. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
    Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
    Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
    >> Share

  124. VALIBOUZE C, Nachury M, Hambli S, Desreumaux P, et al
    Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:1230.
    >> Share

  125. JANSEN FM, den Broeder N, Lubeek SFK, Savelkoul EHJ, et al
    Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study.
    Eur J Gastroenterol Hepatol. 2023;35:1123-1130.
    >> Share

    September 2023
  126. FERRARO S, Cappello E, Bartolini C, Convertino I, et al
    Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002642.
    >> Share

  127. ALHALABI M, Alaa Eddin K, Abbas A
    Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002649.
    >> Share

  128. HONAP S, Irving PM, Samaan MA
    JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002650.
    >> Share

  129. NERI B, D'Agostini G, Salvatori S, Mossa M, et al
    Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
    Eur J Gastroenterol Hepatol. 2023;35:948-954.
    >> Share

    August 2023
  130. ZHANG T, Zhang QD, Jin T, Li WJ, et al
    Is histological healing more clinically valuable than endoscopic healing in Crohn's disease?
    Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002624.
    >> Share

  131. TSAFARIDOU M, Augoustaki A, Koutroubakis I
    Lymphogranuloma venereum and CMV co-infection mimicking ulcerative proctitis in a non-immunocompromised patient.
    Eur J Gastroenterol Hepatol. 2023;35:921-922.
    >> Share

  132. HUANG Y, Su Y, Qin R, Wang L, et al
    Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:854-864.
    >> Share

    July 2023
  133. LYKOWSKA-SZUBER L, Walczak M, Dobrowolska A, Skrzypczak-Zielinska M, et al
    Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002618.
    >> Share

  134. ZHAN Y, Cheng X, Mei P, Wu J, et al
    Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002614.
    >> Share

  135. BOUSTANY A, Rahhal R, Mitri J, Onwuzo S, et al
    The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
    Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002607.
    >> Share

    May 2023
  136. KONSTANTINOU CS, Korantzopoulos P, Fousekis FS, Katsanos KH, et al
    Inflammatory bowel disease and atrial fibrillation: a contemporary overview.
    Eur J Gastroenterol Hepatol. 2023 May 8. doi: 10.1097/MEG.0000000000002562.
    >> Share

  137. HASSAN EA, Abdel Rehim ASE, Ahmed AO, Salim SMAE, et al
    Current insight into enteropathogens in flare-up ulcerative colitis. An observational study.
    Eur J Gastroenterol Hepatol. 2023 May 3. doi: 10.1097/MEG.0000000000002563.
    >> Share

  138. PRENTICE RE, Wright EK, Flanagan E, Kamm MA, et al
    Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility.
    Eur J Gastroenterol Hepatol. 2023;35:609-612.
    >> Share

    April 2023
  139. CHAHAL JK, Sriranganathan D, Poo S, Lo SW, et al
    Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease.
    Eur J Gastroenterol Hepatol. 2023 Apr 11. doi: 10.1097/MEG.0000000000002552.
    >> Share

  140. PRINCIPI M, Macaluso FS, Todeschini A, Facciotti F, et al
    Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Eur J Gastroenterol Hepatol. 2023 Apr 4. doi: 10.1097/MEG.0000000000002550.
    >> Share

    March 2023
  141. NOVAK G, Sever N, Hanzel J, Kozelj M, et al
    Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002543.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016